The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 05, 2020
Filed:
May. 08, 2017
Applicant:
Alligator Bioscience Ab, Lund, SE;
Inventors:
Peter Bo Joakim Ellmark, Lund, SE;
Eva Maria Dahlen, Arlov, SE;
Assignee:
ALLIGATOR BIOSCIENCE AB, Lund, ES;
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61K 49/00 (2006.01); C07K 16/46 (2006.01); A61K 9/00 (2006.01); A61K 9/02 (2006.01); A61K 9/08 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 51/10 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2878 (2013.01); A61K 9/0019 (2013.01); A61K 9/0048 (2013.01); A61K 9/02 (2013.01); A61K 9/08 (2013.01); A61K 9/20 (2013.01); A61K 9/48 (2013.01); A61K 39/3955 (2013.01); A61K 49/00 (2013.01); A61K 51/103 (2013.01); A61K 51/1096 (2013.01); C07K 16/468 (2013.01); A61K 2039/505 (2013.01); A61K 2039/70 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/35 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/75 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01);
Abstract
The present invention relates to antibodies (and fragments, variants, fusions and derivatives thereof) with multivalent binding specificity for CD40, which have a potency for dendritic cell activation which is higher than, or is equal to, the potency for B cell activation and wherein the antibody, antigen-binding fragment, or fusion, variant or derivative thereof has an affinity (KD) for CD40 of less than 1×10M, which have utility in the treatment of diseases such as cancer. The invention also relates to pharmaceutical compositions, uses, methods and kits comprising such antibodies.